#RGX202
LightNews LightNews
dmdwarrior.com
REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

#dmd #duchenne #regenxbio #genetherapy #clinicaltrials #rgx202

👉 Read More: DMDWarrioR.com
REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program REGENXBIO announced it has completed enrollment of 30 participants in the pivotal portion of its AFFINITY DUCHENNE trial for RGX-202, an investigational gene therapy for Duchenne muscular dystrophy.
October 30, 2025 at 1:06 PM
dmdwarrior.com
RGX-202 microdystrophin expression results in ambulatory patients aged 8+ are the highest reported microdystrophin levels across approved or investigational gene therapies.

Source: regenxbio.gcs-web.com/news-release...

#dmd #regenxbio #RGX202 #AFFINITYDUCHENNE #AAV8
REGENXBIO INITIATES TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA REGENXBIO INITIATES TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
November 18, 2024 at 5:15 PM
theakarifoundation.bsky.social
📣 REGENXBIO COMUNICA 

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #REGENXBIO #AFFINITYDUCHENNE #RGX202#somoselcorazóndeladistrofia #AkariMayo
May 14, 2026 at 10:39 PM